Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
Andrea Santamato Physical Medicine and Rehabilitation Section, “OORR Hospital,” University of Foggia, Foggia, Italy Abstract: Spasticity is a common disabling symptom for several neurological conditions. Botulinum toxin type A injection represents the gold standard treatment fo...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2016
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/a46c4cff9f314e0cb8b6987eb9ab881e |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| Résumé: | Andrea Santamato Physical Medicine and Rehabilitation Section, “OORR Hospital,” University of Foggia, Foggia, Italy Abstract: Spasticity is a common disabling symptom for several neurological conditions. Botulinum toxin type A injection represents the gold standard treatment for focal spasticity after stroke showing efficacy, reversibility, and low prevalence of complications. In recent years, incobotulinumtoxinA, a new Botulinum toxin type A free of complexing proteins, has been used for treating several movement disorders with safety and efficacy. IncobotulinumtoxinA is currently approved for treating spasticity of the upper limb in stroke survivors, even if several studies described the use also in lower limb muscles. In the present review article, we examine the safety and effectiveness of incobotulinumtoxinA for the treatment of spasticity after stroke. Keywords: Hypertone, botulinum toxin, incobotulinumtoxinA, onabotulinumtoxinA, abobotulinumtoxinA |
|---|